TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments

Journal of Virology

Volumn 79, Issue 20, 2005, Pages 12773-12782

  Vingerhoets, Johan ^a   Azijn, Hilde ^a   Fransen, Els ^a   De Baere, Inky ^a   Smeulders, Liesbet ^a   Jochmans, Dirk ^a   Andries, Koen ^b   Pauwels, Rudi ^a,d   De Béthune, Marie Pierre ^a,c  

^a Virco BVBA   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c TIBOTEC BVBA   (Belgium)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONCENTRATION RESPONSE; CROSS RESISTANCE; DRUG ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT; VIRUS RESISTANCE; WILD TYPE;

AMINO ACID SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SELECTION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 26444595584     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.20.12773-12782.2005     Document Type: Article

References (35)

1. Ait-Khaled, M., A. Rakik, P. Griffin, C. Stone, N. Richards, D. Thomas, J. Falloon, and M. Tisdale. 2003. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/ amprenavir in the CNA2007 study. Antivir. Ther. 8:111-120.
2. Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M.-P. de Bethune. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
3. Antinori, A., M. Zaccarelli, A. Cingolani, K. Forbici, M. G. Rizzo, M. P. Trotta, S. Di Giambenedetto, P. Narciso, A. Ammassari, E. Girardi, A. De Luca, and C. F. Perno. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res. Hum. Retrovir. 18:835-838.
4. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, U. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
5. Bacheler L. T., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Anjay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasnt, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
6. Balzarini, J., A. Karlsson, V. V. Sardana, E. A. Emini, M. J. Camarasa, and E. De Clercq. 1994. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C⇁C1811)RT HIV-1 mutants. Proc. Natl. Acad. Sci. USA 91:6599-6603.
7. Basavapathruni, A., C. M. Bailey, and K. S. Anderson. 2004. Delining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279:6221-6224.
8. Briones, C., V. Soriano, C. Dona, P. Barreiro, and J. Gonzalez-Lahoz. 2000. Can early failure with nevirapine be rescued with efavirenz? J. Acquir. Immune Defic. Syndr. 24:76-78.
9. Carr, A., S. Vella, M. D. de Jong, F. Sorice, A. Imric, C. A. Boucher, D. A. Cooper, et al. 1996. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 10:635-641.
10. Das, K., A. D. Clark, Jr., P. J. Lewi, J. Heeres, M. R. de Jonge, L. M. Koymans, H. M. Vinkers, F. Daeyaert, D. W. Ludovici, M. J. Kukla, B. De Corte, R. W. Kavash, C. Y. Ho, H. Ye, M. A. Lichtenstein, K. Andries, R. Pauwels, M. P. de Bethone, P. L. Boyer, P. Clark, S. H. Hughes, P. A. Janssen, and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
11. Delaugerre, C., R. Rohban, A. Simon, M. Mouroux, C. Tricot, R. Agher, J. M. Huraux, C. Katlama, and V. Calvez. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 65:445-448.
12. Fujiwara, T., A. Sato, M, el-Farrash, S. Miki, K. Abe, Y. Isaka, M. Kodama, Y. Wu, L. B. Chen, H. Harada, H. Sugimoto, M. Hatanaka, and Y. Hinuma. 1998. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42:1340-1345.
13. Gazzard, B. G., A. L. Pozniak, W. Rosenbaum, G. P. Yeni, S. Staszewski, K. Arasteh, K. De Dier, M. Peeters, B. Woodfall, J. Stebbing, and G. A. van t' Klooster. 2003. An open-label assessment of TMC 125-a new, next-generation NNRT1, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17:F49-F54.
14. Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petropoulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
15. Gruzdev, B., A. Rakhmanova, E., Doubovskaya, A. Yakovlev, M. Peeters, A. Rinehart, K. De Dier, P. Baede-Van Dijk, W. Parys, and G. van 't Klooster. 2003. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 17:2487-2494.
16. Harrigan, P. R., M. Salim, D. K. Stammers, B. Wynhoven, Z. L. Brumme, P. McKenna, B. Larder, and S. D. Kemp. 2002. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J. Virol. 76:6836-6840.
17. Health Protection Agency. 23 October 2003. posting date. HIV drug resistance in the United Kingdom. Communicable Dis. Wkly. Rev. 13:43. [Online.] www.hpa.org.uk/cdr/PDFfiles/2003/cdr4303.pdf.
18. Hertogs, K., M. P. de Béthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
19. Huang, W., A. Gamarnik, K. Limoli, C. J. Petropoulos, and J. M. Whitcomb. 2003. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77:1512-1523.
20. Kuwata, T., Y. Miyazaki, T. Igarashi, J. Takehisa, and M. Hayami. 1997. The rapid spread of recombinants during a natural in vitro infection with two human immunodeficiency virus type 1 strains. J. Virol. 71:7088-7091.
21. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
22. Meyerhans, A., A. Jung, R. Maier, J. P. Vartanian, G. Bocharov, and S. Wain-Ilohson. 2003. The non-clonal and transitory nature of HIV in vivo. Swiss Med. Wkly. 133:451-454.
23. Palmer, S., M. Kearney, K. Maldarelli, E. K. Halvas, C. J. Bixby, H. Bazmi, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, S. Hammer, J. W. Mellors, and J. M. Coffin. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43:406-413.
24. Pelemans, H., A. Aertsen, K. Van Laethem, A. M. Vandamme, E. De Clercq, M. J. Perez-Perez, A. San Felix, S. Velazquez, M. J. Camarasa, and J. Balzarini. 2001. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 280:97-106.
25. Rhodes, T., H. Wargo, and W.-S. Hu. 2003. High rates of human immuno-deficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J. Virol. 77:11193-11200.
26. Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. Bozette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
27. Sbafer, R. W., L. M. Smeaton, G. K. Robbins, V. De Gruttola, S. W. Snyder, R. T. D'Aquila, V. A. Johnson, G. D. Morse, M. A. Nokta, A. I. Martinez, B. M. Gripshover, P. Kaul, R. Hanbrich, M. Swingle, S. D. McCarty, S. Vella, M. S. Hirsch, and T. C. Merigan. 2003. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349:2304-2315.
28. Shulman, N. S., A. R. Zolopa, D. J, Passaro, U. Murlidharan, D. M. Israelski, C. L. Brosgart, M. D. Miller, S. Van Doren, R. W. Shafer, and D. A. Katzenstein. 2000. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J. Acquir. Immune Defic. Syndr. 23:221-226.
29. Squires, K., A. Lazzarin, J. M. Gatell, W. G. Powderly, V. Pokrovskiy, J. F. Delfraissy, J. Jemsek, A. Rivero, W. Rozenbaum, S. Schrader, M. Sension, A. Vibhagool, A. Thiry, and M. Giordano. 2004. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36:1011-1019.
30. Staszewski, S., J. Morales-Ramirez, K. T. Tashima, A. Rachlis, D. Skiest, J. Stanford, R. Stryker, P. Johnson, D. F. Labriola, D. Farina, D. J. Manion, N. M. Ruiz, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 341:1865-1873.
31. Udier-Blagovic, M., J. Tirado-Rives, and W. L. Jorgensen. 2003. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J. Am. Chem. Soc. 125:6016-6017.
32. van der Valk, M., J. J. Kastelein, R. L. Murphy, F. van Leth, C. Katlama, A. Horban, M. Glesby, G. Behrens, B. Clotet, R. K. Stellato, H. O. Molhuizen, and P. Reiss. 2001. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15:2407-2414.
33. Weinstock, H. S., I. Zaidi, W. Heneine, D. Bennett, J. G. Garcia-Lerma, J. M. Douglas, Jr., M. LaLota, G. Dickinson, S. Schwarez, L. Torian, D. Wendell, S. Paul, G. A. Goza, J. Ruiz, B. Boyett, and J. E. Kaplan. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189:2174-2180.
34. Winslow, D. L., S. Garber, C. Reid, H. Scarnati, D. Baker, M. M. Rayner, and E. D. Anton. 1996. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 10:1205-1209.
35. Zhu, Q. Y., A. Scarborough, B. Polsky, and T. C. Chou. 1996. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res. Hum. Retrovir. 12:507-517.